Status:
COMPLETED
Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Neovascular (Wet) Age-related Macular Degeneration
Eligibility:
All Genders
18+ years
Brief Summary
This was a retrospective, observational cohort study. Data were analyzed from the Intelligent Research in Sight (IRIS) registry from October 8, 2019, through November 26, 2021, with a follow-up period...
Eligibility Criteria
Inclusion
- At least 18 years old at the time of their first (index) injection of brolucizumab.
- Had documented neovascular age-related macular degeneration (nAMD) on or within 3 years before the index injection.
- Used only brolucizumab for at least 12 months (± 45 days) after the index injection, with at least 1 brolucizumab injection given within the first 6 months after the index injection and at least 1 additional brolucizumab injection given at 6-12 months after the index injection.
Exclusion
- Had received any other anti-VEGF agent between the index injection and 12-month follow-up.
- Lacked information about the laterality of disease at the time of the index injection.
- Lacked visual acuity assessments on or within 30 days before the index injection or at 6, 9, and 12 months after the index injection (all of the latter ± 45 days).
Key Trial Info
Start Date :
May 31 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 16 2022
Estimated Enrollment :
2079 Patients enrolled
Trial Details
Trial ID
NCT06184360
Start Date
May 31 2022
End Date
December 16 2022
Last Update
December 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
East Hanover, New Jersey, United States, 07936